Approval · Notice of Compliance 19083 · 2017
PAZEO: Notice of Compliance 19083
Issued March 17, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19083
- Date
- March 17, 2017
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Transfer of drug identification number
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PAZEO | 02458551 | Marketed |
Medicinal ingredients
- OLOPATADINE HCL 0.7 PER